Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Youhong Fan
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Integrative Proteomic and Transcriptomic Analysis Provides Evidence for TrkB (NTRK2) as a Therapeutic Target in Combination With Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer
Oncotarget
Oncology
Related publications
Niclosamide Overcomes Acquired Resistance to Erlotinib Through Suppression of STAT3 in Non-Small Cell Lung Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Mechanism Research of miR‐34a Regulates Axl in Non‐small‐cell Lung Cancer With Gefitinib‐acquired Resistance
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Dual Inhibition of EGFR and mTOR Pathways in Small Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
Targeting Heat Shock Protein 90 With CUDC-305 Overcomes Erlotinib Resistance in Non-Small Cell Lung Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Clinical Cancer Research
Cancer Research
Oncology
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines
Journal of Cancer
Oncology
The miR‑625‑3p/AXL Axis Induces Non‑T790M Acquired Resistance to EGFR‑TKI via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer
Oncology Reports
Medicine
Cancer Research
Oncology
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer
Cancer Research
Cancer Research
Oncology
